Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camu camu + ICI
- Development stage
- Unknown
- Lead developer
- Centre hospitalier de l’Université de Montréal
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Camu Camu + ICI is an investigational combination therapy consisting of a prebiotic extract from the Camu Camu berry (Myrciaria dubia) and a standard-of-care immune checkpoint inhibitor (ICI), typically an anti-PD-1 monoclonal antibody. The active prebiotic component is castalagin, a polyphenol that modulates the gut microbiome by specifically enriching for Akkermansia muciniphila. This shift in the microbiome is intended to overcome resistance to ICIs and enhance their antitumor efficacy. Developed by the Centre Hospitalier de l'Université de Montréal (CHUM), the combination is being evaluated in Phase I/II clinical trials for patients with advanced non-small cell lung cancer (NSCLC) and metastatic melanoma, including those who are refractory to prior ICI treatment.
- Other names
- myrciaria dubia + immune checkpoint inhibitorcastalagin + ICIcamu camu prebiotic + ICI
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on camu camu + ICI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camu camu + ICI.